Applied DNA Sciences, Inc. Cash Flow Conversion Efficiency
Applied DNA Sciences, Inc. cash flow conversion efficiency. Based on the latest financial reports, Applied DNA Sciences, Inc. (BNBX) has a cash flow conversion efficiency ratio of -0.169x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.05 Million) by net assets ($12.13 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Applied DNA Sciences, Inc. (2021–2025)
Cash flow conversion efficiency of Applied DNA Sciences, Inc. from 2021 to 2025. This chart illustrates how Applied DNA Sciences, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View Applied DNA Sciences, Inc. (BNBX) share price today for real-time trading data and today's change.
Applied DNA Sciences, Inc. Cash Flow Conversion Ratio Explained
Applied DNA Sciences, Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Applied DNA Sciences, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Applied DNA Sciences, Inc. ranked by their cash flow conversion efficiency. Also see Applied DNA Sciences, Inc. market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CT Global Managed Portfolio Trust PLC
LSE:CMPI
|
0.010x |
|
Companhia Tecidos Santanense Ltda
SA:CTSA3
|
0.074x |
|
Flexituff Ventures International Limited
NSE:FLEXITUFF
|
0.248x |
|
Inti Kapuas Arowana Tbk
JK:IIKP
|
-0.003x |
|
Braemar Plc
LSE:BMS
|
0.012x |
|
Lyc Healthcare Bhd
KLSE:0075
|
2.300x |
|
Corero Network Security plc
LSE:CNS
|
-0.046x |
|
2CUREX AB SEK-10
F:2QE
|
N/A |
Annual Cash Flow Conversion Efficiency for Applied DNA Sciences, Inc. (2021–2025)
The table below shows the annual cash flow conversion efficiency of Applied DNA Sciences, Inc. from 2021 to 2025. Review how financially flexible is Applied DNA Sciences, Inc. to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $1.94 Million | $-12.52 Million | -6.447x | -321.69% |
| 2024-09-30 | $8.97 Million | $-13.71 Million | -1.529x | -19.81% |
| 2023-09-30 | $4.87 Million | $-6.22 Million | -1.276x | -83.51% |
| 2022-09-30 | $12.91 Million | $-8.98 Million | -0.695x | +42.28% |
| 2021-09-30 | $11.11 Million | $-13.39 Million | -1.205x | -- |
About Applied DNA Sciences, Inc.
BNB Plus Corp. provides digital asset treasury services. The company offers real-time data tracking of treasury performance and market indicators. The company, through its subsidiaries, also develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) in the Americas, Europe, Asia, and internationally. The company engages in the enzymatic m… Read more